Your search for ‘Rowe & Maw’ returned 281 results

On January 10, 2006, the Supreme Court heard argument in two consolidated cases — Texaco v. Dagher and Shell Oil v. Dagher — to decide the following question: whether an agreement between owners of a lawful joint venture as to the price that the joint venture sells products in markets in which the owners do not compete is subject to per se condemnation under Section 1 of the Sherman Act.

On November 19, 2003, the Securities and Exchange Commission adopted new requirements that each public company provide disclosures regarding the operations of the nominating committee of its board of directors, as well as the means, if any, by which security holders may communicate with directors.

Today the Supreme Court granted certiorari in four cases of interest to the business community, two of which it consolidated. Amicus briefs in support of the petitioners will be due on November 25, 2005, and amicus briefs in support of the respondents will be due on December 30, 2005

On 6 January 2004 the European Court of Justice ("<B>ECJ</B>") dismissed the appeal by the European Commission<SUP>1</SUP> and others against the Court of First Instance’s ("<B>CFI</B>") decision<SUP>2</SUP> to annul the Commission’s <I>Bayer/Adalat </I>decision.

The European Commission has adopted a new Technology Transfer Block Exemption Regulation, which came into effect on 1 May 2004. The Regulation provides a "safe harbour" from the effects of EU competition rules for certain types of technology licence agreements.

The Securities and Exchange Commission’s new Form 8-K rules, which became effective on August 23, 2004 (available at http://sec.gov/about/forms/form8-k.pdf), require that a Current Report on Form 8-K be filed within four business days after the entry into (or termination of) a material definitive contract which is not made in the ordinary course of business. See our Securities Update entitled "SEC Revises Form 8-K," dated April 5, 2004 (available at http://www.mayerbrownrowe.com/publications/art

The International Competition Network (ICN) is an informal network of antitrust agencies from developed and developing countries around the world. It was launched in October 2001, with the cooperation of antirust officials from 14 jurisdictions: Australia, Canada, the European Union, France, Germany, Israel, Italy, Japan, Korea, Mexico, South America, the United Kingdom, the United States and Zambia. Today, 90 member competition agencies from 80 jurisdictions participate.

On October 26, 2004, the Securities and Exchange Commission voted to propose modifications to the securities registration and offering processes under the Securities Act of 1933. The proposals will address communications related to registered securities offerings, facilitate delivery of information to investors and make other changes in procedures in the offering and capital formation process.

Recently, the Supreme Court granted certiorari in three cases of potential interest to the business community. Amicus briefs in support of the petitioners were due on Friday, November 14, 2003, and amicus briefs in support of the respondents are due on Friday, December 19, 2003.

Council Directive 2001/23/EC of 12 March 2001 (which replaces earlier Directives) is a European Directive which is designed to safeguard the rights of employees if the business in which they work is transferred to a new owner.

Regulation (EC) 1/2003<SUP>1</SUP> ("Regulation 1/2003") which will enter into force on 1 May 2004 brings about a fundamental reform to the procedural rules of European Competition Law.

>Recently the Supreme Court granted certiorari in four cases of interest to the business community, two of which have been consolidated. Amicus briefs in support of petitioners will be due on Friday, November 26, 2004 and amicus briefs in support of respondents will be due on Friday, December 31, 2004.

The Federal Trade Commission ("FTC") has identified health care as one of three FTC target markets, chosen because they "have the biggest impact on consumers." So said FTC Chairman Timothy Muris in a prepared statement before the U.S. House Committee on the Judiciary Antitrust Task Force on July 24, 2003. As part of its overall strategy with respect to the health care market, the FTC has challenged agreements made between drug manufacturers in connection with patent infringement litigation trigg